MTHFR A1298C Does NOT Increase DVT Risk
The MTHFR A1298C variant does not increase the risk of deep vein thrombosis and should not be tested for thrombophilia evaluation. 1
Guideline-Based Recommendation
The 2025 ACMG technical standard explicitly states that there is insufficient clinical evidence to support assessment of MTHFR variants (including A1298C) in the evaluation of thrombophilic etiology for VTE. 1 The guideline clearly recommends against routine MTHFR variant testing for thrombophilia, a position also supported by ACOG and the British Committee for Standards in Haematology. 1
Why This Matters
The historical hypothesis was that MTHFR variants reduce enzyme activity, leading to mild hyperhomocysteinemia, which could theoretically increase VTE risk. However, recent meta-analyses have shown no significant association between MTHFR variants and VTE, fundamentally questioning the clinical utility of such testing. 1
Research Evidence Context
While some individual studies suggest associations, the evidence is contradictory and ultimately does not support clinical action:
No association found: A 1999 British study of 190 DVT patients found MTHFR 1298 A→C in 42.1% of patients versus 41.1% of controls (OR 1.07 for heterozygotes, 0.83 for homozygotes), concluding it does not play a critical role in DVT predisposition. 2
Conflicting data: Some studies report associations in specific populations (South Indians 3, Macedonians 4), but these are population-specific and not generalizable.
Meta-analysis limitations: A 2020 meta-analysis found associations for C677T (not A1298C) primarily in Asian populations, but notably found no relationship between A1298C polymorphism and VTE in any genetic model. 5
Retrospective studies: Small retrospective reviews claiming associations 6, 7, 8 are methodologically weaker than prospective studies and meta-analyses, and contradict guideline-level evidence.
Clinical Pitfalls to Avoid
Do not order MTHFR testing as part of routine thrombophilia workup—it wastes resources and may lead to inappropriate clinical decisions.
If a patient already has MTHFR A1298C results, do not alter anticoagulation decisions based on this finding alone.
Focus testing on validated markers: Factor V Leiden (4-8 fold increased risk for heterozygotes) and Factor II c.*97G>A (2-4 fold increased risk) are the only two genetic variants with sufficient evidence for routine clinical testing. 1
Homocysteine levels do not correlate with MTHFR polymorphisms or VTE risk in a clinically meaningful way, so measuring homocysteine does not add value. 6
What to Test Instead
For patients with personal or family history of VTE, particularly in high-risk scenarios (unusual sites, pregnancy-associated, OC-associated, young age with family history), test only:
- Factor V Leiden
- Factor II c.*97G>A (prothrombin G20210A)